Romiplostim (Nplate)

Romiplostim (Nplate) is covered for chronic immune thrombocytopenia after inadequate response to corticosteroids, IVIG and/or splenectomy and as a compendial treatment for thrombocytopenia due to low‑to‑intermediate‑risk myelodysplastic syndrome, with other indications not supported. Approval is for up to 1 year, requires hematology (or hematology/oncology for MDS) involvement, documentation of prior therapy or splenectomy for chronic ITP (and MDS risk status plus clinically significant thrombocytopenia for MDS), and adherence to specified dosing (chronic ITP titration from 1 mcg/kg weekly up to a 10 mcg/kg weekly maximum; MDS per listed mcg regimens).

"Nplate (romiplostim) is indicated for the treatment of thrombocytopenia in individuals with chronic immune thrombocytopenia who had an insufficient response to corticosteroids, immunoglobulins, and..."

Sign up to see full coverage criteria, indications, and limitations.